Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

Shi, Yuankai<sup>*</sup>; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Aimin; Cui, Jiuwei; Feng, Jian; Yang, Nong; Liu, Fei; Jiang, Yong; Gu, Chuan

doi:10.1016/S2213-2600(22)00168-0

免费注册

赞分享引用

科研之友

微信

新浪微博

Facebook

分享链接

Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

作者：Shi, Yuankai^*; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Aimin; Cui, Jiuwei; Feng, Jian; Yang, Nong; Liu, Fei; Jiang, Yong; Gu, Chuan

来源：Lancet Respiratory Medicine, 2022, 10(11): 1019-1028.

DOI：10.1016/S2213-2600(22)00168-0